A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy
… 10) is the fourth-generation EGFR inhibitor obtained by high-throughput screening (HTS)
strategy from a library of 2.5 million compounds at 1 µM ATP concentration. EAI001 57 is a …
strategy from a library of 2.5 million compounds at 1 µM ATP concentration. EAI001 57 is a …
[PDF][PDF] Review on epidermal growth factor receptor (EGFR) structure, signaling pathways, interactions, and recent updates of EGFR inhibitors
… epidermal growth factor receptor (EGFR) belongs to the ERBB family of tyrosine kinase
receptors… tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human …
receptors… tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human …
Epidermal growth factor receptor (EGFR) involvement in epithelial‐derived cancers and its current antibody‐based immunotherapies
M London, E Gallo - Cell biology international, 2020 - Wiley Online Library
… epithelial-derived tumors, and associated with poor prognosis and survival in cancer patients.
Here, we discuss in detail the role of EGFR in specific epithelial-derived … -EGFR therapies. …
Here, we discuss in detail the role of EGFR in specific epithelial-derived … -EGFR therapies. …
[HTML][HTML] Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives
E Martinelli, D Ciardiello, G Martini, T Troiani… - Annals of …, 2020 - Elsevier
… EGFR inhibition in second-line therapy of mCRC patients after progression from first-line
treatment … Third-line treatment in patients with RAS WT mCRC who obtained a PR/CR in first …
treatment … Third-line treatment in patients with RAS WT mCRC who obtained a PR/CR in first …
Natural tyrosine kinase inhibitors acting on the epidermal growth factor receptor: Their relevance for cancer therapy
Y Liang, T Zhang, J Zhang - Pharmacological Research, 2020 - Elsevier
… As the significant approach in the cancer targeted therapy, synthetic EGFR-TKIs have been
… conclusion, EGFR-TKIs are the standard first-line treatment to patients with advanced EGFR-…
… conclusion, EGFR-TKIs are the standard first-line treatment to patients with advanced EGFR-…
Revisiting Epidermal Growth Factor Receptor (EGFR) Amplification as a Target for Anti-EGFR Therapy: Analysis of Cell-Free Circulating Tumor DNA in Patients With …
S Kato, R Okamura, M Mareboina, S Lee… - JCO precision …, 2019 - ascopubs.org
… We investigated the genomic landscape of EGFR amplification in blood-derived cell-free …
who received EGFR inhibitors. Incorporating EGFR inhibitors into the treatment regimens of …
who received EGFR inhibitors. Incorporating EGFR inhibitors into the treatment regimens of …
First‐line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non‐squamous non‐small cell lung cancer
J Greenhalgh, A Boland, V Bates… - Cochrane Database …, 2021 - cochranelibrary.com
… We will derive and display ranking probabilities for each treatment using the Surface Under
the … Overall, there was a lack of data on the OS benefit of EGFR inhibitors, but with a low …
the … Overall, there was a lack of data on the OS benefit of EGFR inhibitors, but with a low …
[HTML][HTML] Molecular targeting of epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR)
… applications in the detection and treatment of cancer. This … show limited wild-type EGFR
inhibition. Therefore these drugs do … derivatives and used in tumor imaging and treatment [173]. …
inhibition. Therefore these drugs do … derivatives and used in tumor imaging and treatment [173]. …
Discovery of potent and selective epidermal growth factor receptor (EGFR) bifunctional small-molecule degraders
… the 9–14 months of treatment. (10−13) To overcome the resistance, a number of the
second-generation EGFR inhibitors targeting EGFR harboring T790M activating mutation have been …
second-generation EGFR inhibitors targeting EGFR harboring T790M activating mutation have been …
[HTML][HTML] Efficacy and safety of epidermal growth factor receptor (EGFR) inhibitors plus antiangiogenic agents as first-line treatments for patients with advanced EGFR …
F Chen, N Chen, Y Yu, J Cui - Frontiers in Oncology, 2020 - frontiersin.org
… the use of EFGR-TKIs plus angiogenesis inhibitors as a first-line therapy for NSCLC. Mesh
and entry … prescribed drugs were checked to further derive qualified publications. Further, we …
and entry … prescribed drugs were checked to further derive qualified publications. Further, we …